$0.60
1.71%
Nasdaq, Mon, Nov 25 2024
ISIN
US15116C1027
Symbol
APOP
Sector
Industry

Cellect Biotechnology Ltd Sponsored ADR Stock price

$0.60
-0.21 26.36% 1M
-0.15 19.59% 6M
-4.31 87.87% YTD
-3.91 86.78% 1Y
-690.91 99.91% 3Y
-1,493.05 99.96% 5Y
-14,984.41 100.00% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.01 1.71%
ISIN
US15116C1027
Symbol
APOP
Sector
Industry

Key metrics

Market capitalization $3.00m
Enterprise Value $-7.31m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.82
P/B ratio (TTM) P/B ratio 0.55
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-9.39m
Free Cash Flow (TTM) Free Cash Flow $-8.90m
Cash position $10.31m
EPS (TTM) EPS $-4.08
P/E forward negative
Short interest 8.32%
Show more

Is Cellect Biotechnology Ltd Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Cellect Biotechnology Ltd Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Cellect Biotechnology Ltd Sponsored ADR forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Cellect Biotechnology Ltd Sponsored ADR forecast:

Buy
100%

Financial data from Cellect Biotechnology Ltd Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.10 0.10
0% 0%
-
-0.10 -0.10
0% 0%
-
- Selling and Administrative Expenses 5.91 5.91
2% 2%
-
- Research and Development Expense 3.28 3.28
11% 11%
-
-9.29 -9.29
2% 2%
-
- Depreciation and Amortization 0.10 0.10
0% 0%
-
EBIT (Operating Income) EBIT -9.39 -9.39
2% 2%
-
Net Profit -8.75 -8.75
2% 2%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cellect Biotechnology Ltd Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. The company was founded by Kasbian Nuriel Chirich, Shai Yarkoni, and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.

Head office Israel
CEO Michael Myers
Employees 4
Founded 2018
Website www.quoinpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today